Agnucaston is generally relevant for conditions associated with premenstrual syndrome (PMS). Its therapeutic benefit is centered on easing the overall symptom load and supporting women during periods of cyclical discomfort.

The medication is commonly used to help with symptom clusters that may become intense or disruptive, including cyclical breast tenderness (mastodynia), mood swings, irritability, and bloating. Applied across domains where additional symptomatic support is needed, it assists with maintaining functional stability when symptoms are more noticeable. This product may play a role in managing and supporting the stabilization of the menstrual pattern in situations involving recurrent or episodic manifestations.

“This preparation supports patients during difficult episodes by helping to ease the overall symptom burden and contributes to improved comfort.”

Quick Fact: Focus area: Cyclical Physical Discomfort

Agnucaston’s official eligibility profile is strictly defined by regulatory guidelines based on age, life stage, and specific medical conditions.

Eligibility Scope

Category	Eligibility Status
Allowed Use	Female adults 18 years of age and above.
Contraindicated	Patients with Hypersensitivity to the active substance or excipients.
Not Recommended	Children and adolescents under 18 years of age (safety and efficacy not established).
Life Stage Exclusion	Pregnancy and Lactation (must not be used; risk cannot be excluded).

---

Condition-Specific Restrictions

Use is restricted and requires mandatory consultation with a doctor for individuals with certain medical histories. This includes patients who have suffered from or currently have an oestrogen-sensitive malignant tumour or a pituitary disorder.

Intake is also restricted in cases of prolactin-secreting tumours of the pituitary gland, as the product may mask the symptoms of the tumour. Additionally, no data is available regarding the safety or required dosage for patients with impaired kidney or liver function.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Agnucaston, which contains Vitex Agni Casti Fructuum Extract, based on regulatory information from authoritative government health agencies.

The interaction profile is primarily structured around potential pharmacodynamic consequences stemming from the extract's established biological activity. No specific pharmacokinetic, metabolic (e.g., CYP enzyme), or transporter-mediated interactions are formally detailed in regulatory labeling.

---

Documented Interaction Categories

Official regulatory documents emphasize a risk assessment based on the active ingredient’s properties. Interactions with the following categories cannot be excluded:

• Dopamine Agonists and Dopamine Antagonists: Potential interaction exists due to the product's possible dopaminergic effects, which may result in either additive or antagonistic actions.
• Oestrogens and Antioestrogens (anti-estrogen medicinal products): Potential interaction exists due to the plant extract's possible oestrogenic effects on the hormonal system.

---

Restrictions and Limitations

Contraindicated Combinations:

• No combinations are classified as strictly prohibited due to a drug-drug interaction risk in the regulatory monograph.

Timing or Separation Requirements:

• No mandatory dose timing or administration separation rules are officially documented in the labeling.

Food, Alcohol, or Supplements:

• No specific interactions with food, alcohol, or other herbal products are formally documented within the regulatory interaction sections.

How Agnucaston Works: Mechanism of Action

Dopaminergic Signaling Modulation

Agnucaston exerts its primary action by acting as an agonist at dopamine D2 receptors located primarily within the anterior pituitary gland. The compounds within the drug bind to these receptors, initiating an inhibitory signaling cascade. This interaction modulates the neuroendocrine feedback loop, specifically suppressing the release and secretion of the hormone prolactin from the pituitary lactotroph cells. This results in a decreased systemic concentration of prolactin.

Hormonal Pathway Regulation

The reduction in prolactin activity alters the homeostatic balance of the hypothalamic-pituitary-ovarian (HPOA) axis. The change in the prolactin concentration modifies the subsequent synthesis and secretion ratios of other key reproductive hormones, including progesterone and estrogen. This cascade leads to specific modulations within the peripheral hormonal feedback system, affecting the cyclical patterns of hormonal activity.

Anti-inflammatory Mediator Engagement

Separately, the drug engages mechanisms that influence inflammatory processes in peripheral tissues. Specifically, certain components act as inhibitors of the enzyme 5-lipoxygenase (5-LOX). This enzymatic inhibition curtails the biosynthesis of pro-inflammatory mediators known as leukotrienes, thereby modifying local cellular signaling and reducing the systemic concentration of these inflammatory molecules.

The principles guiding the administration of Agnucaston follow a standardized approach to its use. The medicine, which utilizes a Vitex agnus-castus extract, is intended for oral use and is supplied as standardized film-coated tablets or a measured liquid solution.

Administration Scope

The standard dosing pattern involves the intake of a preparation corresponding to a specific extract amount. The daily dose for the standardized extract is generally 20 mg. The standard frequency involves administration once daily, a schedule designed to simplify adherence to the treatment plan.

Feature	Guideline
Route of administration	Oral use
Dosing schedule	Once daily, typically 20 mg dry extract equivalent
Age-group rules	Use not recommended under 18 years of age
Course duration	Continuous administration for three months

Resulting Procedural Structure

A critical aspect of the usage protocol is the course duration. Administration should be continuous for three months to align with the intended application. If the condition of use persists after this designated three-month period, professional medical review is the procedural next step.

This framework outlines the observed procedural steps:

• Administer the fixed dose via the oral route once daily.
• Maintain continuous administration for three months.
• Initiate a clinical review if symptoms associated with the use persist after the defined course duration.

This structured protocol describes the route, frequency, and duration of use, ensuring that administration adheres to the standardized parameters.

Evidence for Use in Premenstrual Syndrome (PMS)

Research exploring the Vitex agnus-castus extract in Agnucaston was studied for women experiencing conditions characterized by fluctuating or episodic manifestations known as Premenstrual Syndrome (PMS). The main evidence is drawn from short-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies monitored outcomes related to physical discomfort, such as bloating, and emotional and psychological indices, like irritability and mood changes, over defined trial intervals. Some trials reported a distinction in the measured symptom outcomes when compared to placebo. This extensive bibliographic evidence contributed to a regulatory conclusion recognizing extensive bibliographic evidence for the preparation in this indication.

The active ingredient was also evaluated in specific clinical studies that examined outcomes related to cyclical breast pain and tenderness (mastodynia). Research findings contribute to the broader evidence landscape and help contextualize how symptoms may evolve during the observed periods. Data for specific patient groups, such as older adult women, remain insufficient.

---

Understanding Uncertainty and Research Gaps

The evidence highlights what is known—and what is still uncertain—about the extract. The core clinical research generally observed responses over two to six menstrual cycles (short-term to intermediate-term follow-up). Because follow-up durations were limited in many primary studies, long-term effects are not fully established.

Evidence quality varies across studies due to methodological heterogeneity and inconsistent diagnostic criteria in older reports. Research explored direct comparisons against established pharmaceutical treatments; however, comparative evidence is limited. The variability in standardization of the extract across the full body of published research can also make definitive conclusions about all preparations uncertain. This research provides context but does not determine whether an individual will respond similarly.

Common questions about Агнукастон (FAQ)

Q: How long does it usually take for a person to notice an effect from taking Агнукастон? / Is it typical to experience no symptom changes during the first month of using Агнукастон?

A: Official product information indicates that the effects of this medicine may not be immediate. To give the product time to achieve its expected objective, continuous administration is specified for a period of three months. It is therefore not unusual to see limited symptom changes in the very first month of use.

Q: Is Агнукастон intended for long-term use, or is it only for short treatment cycles?

A: The course duration specified in regulatory documentation is continuous administration for three months. If the symptoms persist after this designated period, professional medical guidance should be sought. The product is not intended for indefinite long-term use without a medical review.

Q: Is the primary function of Агнукастон to regulate the timing of the menstrual cycle?

A: The active ingredient is traditionally used to relieve a variety of common complaints related to the menstrual cycle, including premenstrual syndrome (PMS) and breast tenderness. The indications also include support for the relief of menstrual cycle irregularities.

Q: Does Агнукастон replace standard hormonal treatments used for menstrual cycle issues?

A: Because the active ingredient may have oestrogenic (hormone-like) effects, official labeling advises caution. Medical guidance should be sought if you are taking oestrogens or anti-oestrogens. This step helps clarify the product's role alongside other hormonal treatments.

Q: How frequently do people experience minor side effects like headaches or dizziness while taking Агнукастон?

A: Regulatory safety documents list nervous system effects such as headache and dizziness as possible adverse reactions. However, the official frequency rate for these particular effects is classified as 'not known.' This means the rate cannot be reliably estimated from the available safety data.

Q: Is it safe to use Агнукастон at the same time as combined or progestin-only birth control pills?

A: The product may have oestrogenic effects, and interaction with other medicines containing oestrogens cannot be ruled out. This category of medicines includes certain contraceptives. Due to this potential interaction, it is advised to seek medical guidance before combining them.

Q: What are 'dopamine agonists' and 'antagonists' and why is their interaction with Агнукастон noted?

A: The interaction is noted because Агнукастон is documented to have dopaminergic effects, meaning it influences certain brain chemical pathways. Dopamine agonists and antagonists are classes of medicine that also affect these same pathways. It is important to seek medical guidance to assess any risks of combining them.

Q: Is the extract found in the official Агнукастон product different from the generic Vitex Agnus Castus sold as a food supplement?

A: The product's regulatory status differs. Агнукастон is classified as a Traditional Herbal Medicinal Product. This classification requires a specific quality, standardization, and verification of the active extract, which is not required for a general food supplement.

Q: Does Агнукастон help with symptoms other than premenstrual syndrome or breast discomfort?

A: In addition to its primary use for symptoms of PMS and cyclical breast tenderness, the active ingredient is traditionally used for broader complaints. Traditional use reports acknowledged by some authorities include the relief of symptoms related to menstrual cycle irregularities and menopausal complaints.

Q: Is Агнукастон classified as a prescription medicine or can it be purchased without one?

A: This product is regulated as a Traditional Herbal Medicinal Product. It is generally intended for over-the-counter use, provided the user is an adult and meets the official eligibility and contraindication criteria listed in the labeling.

Q: Is weight change or fluid retention a commonly reported side effect of Агнукастон?

A: According to published regulatory data, side effects reported in users have included weight gain, which is generally listed as an uncommon event. Reports of fluid retention are not commonly highlighted in the official adverse reaction summaries.

Q: Can taking Агнукастон cause a change in a person's mood or feelings of anxiety?

A: The product's intended use is to help relieve common PMS mood symptoms such as irritability and mood swings. Separately, the official list of adverse reactions includes nervous system effects like headache and dizziness, but mood changes are not listed as side effects.

Q: Is Агнукастон generally suitable for women who are in the perimenopausal stage?

A: The active ingredient is traditionally used for symptoms associated with the menstrual cycle. This traditional use also covers complaints related to the perimenopausal and menopausal stages.

Q: Is there an established concern with using Агнукастон if a person has a history of depression or an anxiety disorder?

A: Medical guidance is advised if you are taking any medicines that affect the brain, such as antipsychotic medications, due to the drug's dopaminergic activity. Medical guidance is also important if there is a history of a pituitary disorder.

Official Storage and Disposal Requirements

Storage of Agnucaston (Vitex Agnus Casti Fructuum Extract) must adhere to official label instructions to maintain product quality.

• Temperature: Some regulatory documents specify storage below 30 C or not above 25 C, while others state no special storage conditions are required. The product should be stored at room temperature, avoiding excessive heat.
• Protection: The medicine must be stored in the original packaging to protect it from light and moisture. For specific liquid forms, the container must be kept tightly closed.
• Child Safety: Agnucaston must be kept out of the sight and reach of children.
• Stability: Do not use the medicine after the expiry date (EXP) printed on the packaging.
• Disposal: Unused or expired Agnucaston should not be disposed of via household waste or wastewater. Consult a pharmacist for instructions on proper pharmaceutical waste disposal in your local area.